Table 1.
Shifts in Gene Expression With Blast Transformation
| Gene Expression | Median Normalized Expression Levels |
TKI-r CML From New CML |
TKI-r CML From CML-MBP |
TKI-r CML From CML-LBP |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| New CML (54 CP, 14 AP) | TKI-r CML | CML MBP | CML LBP | P | P adj* | P | P adj* | P | P adj* | |
| Most increased with blast transformation | ||||||||||
| ABCC1 | 0.479 | 0.910 | 1.617 | 2.697 | < .001 | < .001 | < .001 | .005 | < .001 | < .001 |
| CD34 | 0.166 | 0.008 | 3.194 | 4.67 | < .001 | < .001 | < .001 | < .001 | < .001 | < .001 |
| FZD7 | 0.025 | 0.020 | 0.09 | 0.083 | .198 | .99 | .001 | .01 | .002 | .01 |
| Most decreased with blast transformation | ||||||||||
| CEBPA | 1.458 | 0.635 | 0.439 | 0.472 | < .001 | < .001 | < .001 | .005 | .001 | .01 |
| JAK2 | 2.762 | 1.604 | 0.720 | 0.884 | < .001 | < .001 | < .001 | < .001 | < .001 | < .001 |
| LYN | 53.190 | 18.375 | 4.076 | 2.897 | < .001 | < .001 | < .001 | < .001 | < .001 | < .001 |
| PTPN22 | 13.944 | 4.513 | 2.759 | 1.686 | < .001 | < .001 | < .001 | .005 | < .001 | < .001 |
| SLC22A1 | 0.180 | 0.328 | 0.02 | 0.040 | .01 | .084 | < .001 | < .001 | < .001 | < .001 |
| STAT3 | 6.364 | 6.916 | 4.286 | 4.877 | .446 | 1 | < .001 | .002 | .003 | .014 |
| STAT5B | 2.542 | 2.670 | 0.993 | 1.000 | .47 | 1 | < .001 | < .001 | < .001 | < .001 |
Abbreviations: TKI-r, tyrosine kinase inhibitor resistance; CML, chronic myelogenous leukemia; MBP, myeloid blast phase; LBP, lymphoid blast phase; CP, chronic phase; AP, accelerated phase.